hi; you made great buy..R&D firm like INCY,earning is less important,in this case nobody is looking for earning provided loose is so hugh that concern stockholders to star thinking about "HOW LONG money in bank last"..this is not case here...MOST IMPORTANT is current drug testing progress report...must have been good...not seen details. I have strong confidence that JAK drug is low toxicity formula that high probability it will come through OK ...that is reason it gets strong support from very smart experienced investors(buyers of secondary) ..Hold your shares until FDA approval..I use to work for PFE in R&D...they don't supponsor drug development of outsiders without detail DD and only blockbuster candidates...Good LUCK..INCY is my biggest holding now.